Targeting IDH1 and IDH2 Mutations in Acute Myeloid Leukemia: Emerging Options and Pending Questions

Abstract excerpt

With a combined prevalence of approximately 20%, mutations in isocitrate dehydrogenase 1 (IDH1) and IDH2 are among the most recurrent genetic abnormalities in newly diagnosed acute myeloid leukemia (AML).1 The high frequency of IDH mutations and the fact that IDH mutations induce a gain in enzymatic activity have led to the development of targeted inhibitors of mutated IDH proteins. These efforts have shown to be...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Acute Myeloid Leukemia Research
• Share to Epigenetics and DNA Methylation
• Share to Histone Deacetylase Inhibitors Research